Recall – Vigabatrin for Oral Solution USP

December 12, 2023
TOPIC: Vigabatrin for Oral Solution USP, 500 mg by InvaGen Pharmaceuticals: Recall – Due to Leaking Sachets

AUDIENCE: Patient, Health Professional, Pharmacy, Pediatric, Neurology

ISSUE: InvaGen Pharmaceuticals is recalling one lot, NB301030, of Vigabatrin for Oral Solution, USP, 500 mg, because it has been found to have seal integrity issues allowing for powder leakage from the pouch.

An improper seal in the pouch may lead to the leakage of powder blend outside the pouch, resulting in a lower content of medicine inside the pouch compared to the label claim and result in potential underdosing. The population at risk is primarily infants and young children. In those patients, there is a reasonable probability that inaccurate dosing might result in a serious adverse effect such as intoxication or breakthrough seizures requiring medical intervention. For a small minority of patients, who might have severe or repeated breakthrough seizures, a drop in their phenytoin blood levels could result in life-threatening seizures requiring immediate emergency room treatment. The Vigabatrin for Oral Solution USP, 500 mg product was distributed nationwide.

To date, Cipla has not received any reports of adverse events related to this recall.

For more information about this recall, click on the red button “Read Recall” below.

BACKGROUND: The product being recalled is used for the treatment of refractory complex partial seizures as adjunctive therapy in patients 2 years of age and older who have inadequately responded to several alternative treatments. Vigabatrin for oral solution is not indicated as a first-line agent.


  • Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this batch of drug product.
  • Patients with questions regarding this recall can contact Cipla.
  • Distributors, retailers and consumers in possession of the recalled Vigabatrin for Oral Solution USP, 500 mg are advised to initiate the return process through their respective place of purchase.
Health professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program:

  • Complete and submit the report online.
  • Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on form, or submit by fax to 1-800-FDA-0178.

Read Recall Button

Related Posts

FDA Warns of Rare but Serious Drug Reaction

FDA Warns of Rare but Serious Drug Reaction

The Dup15q Alliance is aware of the recent release by the FDA regarding Keppra, Keppra XR, Elepsia XR, Spritam (levetiracetam) and Onfi, Sympazan (clobazam) warning about the risk of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). This adverse event is...

Medication Recall Alert Sabril® (Vigabatrin)

Medication Recall Alert Sabril® (Vigabatrin)

Our friends at the Epielpsy Foundation have shared the Following Medication Recall The company that makes Sabril® (vigabatrin) for oral solution, a prescription medication to manage seizures in children and adults, has announced a recall of this medication because of...



We understand that some families in our community may be having challenges getting prescriptions filled for generic Felbamate oral suspension and tablets. If you need assistance with obtaining your medication, contact our 24/7 Helpline at 1-800-332-1000 for connection...